Source link : https://www.newshealth.biz/health-news/mirikizumab-effective-in-crohns-disease-after-initial-standard-therapy-failure/
Mirikizumab (Omvoh) improved outcomes in patients with moderately-to-severely active Crohn’s disease with previous failure to standard therapy, a phase III randomized trial showed. Among over 1,000 patients in the efficacy population, 38% of those taking mirikizumab met the composite endpoint of patient-reported outcome (PRO) clinical response at week 12 and endoscopic response at week 52 […]
Author : News Health
Publish date : 2024-11-29 13:00:00
Copyright for syndicated content belongs to the linked Source.
inHealth